Statins reduce macrophage inflammatory protein-1α expression in human activated monocytes

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 12, 2006, Pages 1144-1149

  Bruegel, Mathias ^a   Teupser, Daniel ^a   Haffner, Ivonne ^a   Mueller, Marc ^a   Thiery, Joachim ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Atherosclerosis; Chemokine; Inflammation; Macrophage inflammatory protein 1 ; Monocytes; Statins

Indexed keywords

CERIVASTATIN; CHOLESTEROL; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; SIMVASTATIN;

ARTICLE; CELL ACTIVATION; CELL ISOLATION; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MONOCYTE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION;

CELL SEPARATION; CELLS, CULTURED; DNA, COMPLEMENTARY; GENES, REPORTER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOASSAY; LUCIFERASES; MACROPHAGE INFLAMMATORY PROTEIN-1; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION, GENETIC;

EID: 33845522700     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04493.x     Document Type: Article

References (28)

1. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-26.
2. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1712-19.
3. Gotto Jr AM, Farmer JA. Pleiotropic effects of statins: Do they matter? Curr. Opin. Lipidol. 2001; 12: 391-4.
4. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
5. Yoshida M, Sawada T, Ishii H et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1165-71.
6. Teupser D, Bruegel M, Stein O, Stein Y, Thiery J. HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells. Biochem. Biophys. Res. Commun. 2001; 289: 838-44.
7. Damas JK, Waehre T, Yndestad A et al. Interleukin-7-mediated inflammation in unstable angina: Possible role of chemokines and platelets. Circulation 2003; 107: 2670-6.
8. Ortego M, Bustos C, Hernandez-Presa MA et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-61.
9. Bustos C, Hernandez-Presa MA, Ortego M et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll Cardiol. 1998; 32: 2057-64.
10. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162: 156-9.
11. Blum S, Forsdyke RE, Forsdyke DR. Three human homologs of a murine gene encoding an inhibitor of stem cell proliferation. DNA Cell Biol. 1990; 9: 589-602.
12. Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res. 1984; 12: 1687-96.
13. Lee SC, Brummet ME, Shahabuddin S et al. Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes. J. Immunol. 2000; 164: 3392-401.
14. Fahey 3rd TJ, Tracey KJ, Tekamp-Olson P et al. Macrophage inflammatory protein 1 modulates macrophage function. J. Immunol. 1992; 148: 2764-9.
15. Cook DN, Beck MA, Coffman TM et al. Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995; 269: 1583-5.
16. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 1993; 260: 355-8.
17. Lloyd AR, Oppenheim JJ, Kelvin DJ, Taub DD. Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matrix proteins. J. Immunol. 1996; 156: 932-8.
18. Hayes IM, Jordan NJ, Towers S et al. Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler. Thromb. Vasc. Biol. 1998; 18: 397-403.
19. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of inflammatory cytokines in human atherosclerotic plaques. J. Atheroscler. Thromb. 1994; 1 (Suppl.): S10-13.
20. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999; 147: 213-25.
21. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos DT. Serum profiles of C-C chemokines in acute myocardial infarction: Possible implication in postinfarction left ventricular remodeling. J. Interferon Cytokine Res. 2002; 22: 223-9.
22. Waehre T, Damas JK, Gullestad L et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J. Am. Coll. Cardiol. 2003; 41: 1460-7.
23. Romano M, Diomede L, Sironi M et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest 2000; 80: 1095-100.
24. Martinez-GonzaleZ J, Alfon J, Berrozpe M, Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001; 159: 27-33.
25. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
26. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997; 11: 2295-322.
27. Bischoff H, Heller AH. Preclinical and clinical pharmacology of cerivastatin. Am. J. Cardiol. 1998; 82: J18-25.
28. Stein E, Isaacsohn J, Stoltz R et al. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Am. J. Cardiol. 1999; 83: 1433-6.